IMT is the first company to target the root cause of autoimmunity with therapeutic design directed at HLA variants known to confer high disease risk. The Company platform builds drug molecules for specific blockade of an HLA protein in a given autoimmune disease as a novel paradigm in drug development. Our drug development of oral therapies employs a unique approach to balance the affinity to HLA binding site(s) to achieve bl...
IMT is the first company to target the root cause of autoimmunity with therapeutic design directed at HLA variants known to confer high disease risk. The Company platform builds drug molecules for specific blockade of an HLA protein in a given autoimmune disease as a novel paradigm in drug development. Our drug development of oral therapies employs a unique approach to balance the affinity to HLA binding site(s) to achieve blockade versus protecting inherent immunity against pathogens conferred by the HLA proteins.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.